These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 23350049)

  • 21. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
    Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heartburn and regurgitation have different impacts on life quality of patients with gastroesophageal reflux disease.
    Lee SW; Lien HC; Lee TY; Yang SS; Yeh HJ; Chang CS
    World J Gastroenterol; 2014 Sep; 20(34):12277-82. PubMed ID: 25232262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of gastroesophageal reflux disease in Uygur and Han Chinese adults in Urumqi.
    Niu CY; Zhou YL; Yan R; Mu NL; Gao BH; Wu FX; Luo JY
    World J Gastroenterol; 2012 Dec; 18(48):7333-40. PubMed ID: 23326142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of distribution of intraesophageal pH during nighttime recumbency among patients with gastroesophageal reflux disease.
    Hershcovici T; Jha LK; Fass R
    J Clin Gastroenterol; 2012 Aug; 46(7):562-6. PubMed ID: 22476040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of body weight on clinical symptoms and endoscopic changes in patients with gastroesophageal reflux disease.
    Krakowska-Stasiak M; Cibor D; Sałapa K; Owczarek D; Mach T
    Przegl Lek; 2016; 73(5):271-5. PubMed ID: 29629738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Esophageal Nocturnal Baseline Impedance and Post-reflux Swallow-induced Peristaltic Wave Index in Identifying Proton Pump Inhibitor-refractory Non-erosive Reflux Disease.
    Wang Y; Ye B; Wang M; Lin L; Jiang L
    J Neurogastroenterol Motil; 2021 Oct; 27(4):525-532. PubMed ID: 34642272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastroesophageal reflux disease management according to contemporary international guidelines: a translational study.
    Pace F; Riegler G; de Leone A; Dominici P; Grossi E;
    World J Gastroenterol; 2011 Mar; 17(9):1160-6. PubMed ID: 21448420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Therapeutic and Diagnostic Value of 2-week High Dose Proton Pump Inhibitor Treatment in Overlapping Non-erosive Gastroesophageal Reflux Disease and Functional Dyspepsia Patients.
    Kriengkirakul C; Patcharatrakul T; Gonlachanvit S
    J Neurogastroenterol Motil; 2012 Apr; 18(2):174-80. PubMed ID: 22523726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Symptom overlaps between functional heartburn, functional dyspepsia, and irritable bowel syndrome].
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 May; 45(3):489-92. PubMed ID: 24941825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
    Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
    Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Prevalence and Clinical Features of Non-responsive Gastroesophageal Reflux Disease to Practical Proton Pump Inhibitor Dose in Korea: A Multicenter Study.
    Park HJ; Park SH; Shim KN; Kim YS; Kim HJ; Han JP; Kim YS; Bang BW; Kim GH; Baik GH; Kim HH; Park SY; Kim SS
    Korean J Gastroenterol; 2016 Jul; 68(1):16-22. PubMed ID: 27443619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determinants of symptoms in gastroesophageal reflux disease: nonerosive reflux disease, symptomatic, and silent erosive reflux disease.
    Choi JY; Jung HK; Song EM; Shim KN; Jung SA
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):764-71. PubMed ID: 23459104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics of symptom presentation and risk factors in patients with erosive esophagitis and nonerosive reflux disease.
    Lee SW; Lee TY; Lien HC; Yang SS; Yeh HZ; Chang CS
    Med Princ Pract; 2014; 23(5):460-4. PubMed ID: 25012767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of heartburn resolution and erosive esophagitis in patients with GERD.
    Orlando RC; Monyak JT; Silberg DG
    Curr Med Res Opin; 2009 Sep; 25(9):2091-102. PubMed ID: 19601705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease.
    Pace F; Pace M
    Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):423-7. PubMed ID: 20678016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
    Simadibrata DM; Lesmana E; Fass R
    J Gastroenterol Hepatol; 2024 May; 39(5):796-805. PubMed ID: 38263507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Esophageal intraluminal baseline impedance differentiates gastroesophageal reflux disease from functional heartburn.
    Kandulski A; Weigt J; Caro C; Jechorek D; Wex T; Malfertheiner P
    Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1075-81. PubMed ID: 25496815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia.
    Asaoka D; Nagahara A; Hojo M; Matsumoto K; Ueyama H; Matsumoto K; Izumi K; Takeda T; Komori H; Akazawa Y; Shimada Y; Osada T; Watanabe S
    Biomed Rep; 2017 Feb; 6(2):175-180. PubMed ID: 28357069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.